An analyst says Boston Scientific has suspended all sales of its implantable cardioverter defibrillators after finding a documentation error in regulatory filings.
Bernstein senior analyst Derrick Sung says in a research note the error puts the Natick, Mass., medical device maker's devices out of compliance with Food and Drug Administration …
Комментариев нет:
Отправить комментарий